Patient blood management is an evidence-based and multidisciplinary approach to caring for patients who might need a blood transfusion. It encompasses all aspects of the transfusion decision-making process, beginning with the initial patient evaluation and continuing through clinical management. These techniques are designed to ensure optimal patient outcomes while maintaining the blood supply to guarantee that blood components are available for patients when they are needed.
Patient Blood Management improves patient outcomes by improving the patient’s medical and surgical management in ways that boost and conserve the patient’s own blood. Owing to better management, patients usually require fewer transfusions of donated blood components, thus avoiding transfusion-associated complications. The National Blood Authority of Australia is funding and managing the development of evidence-based patient blood management guidelines.
Major factors driving the growth of the patient blood management market include a rise in technological advancement in patient blood management devices, an increase in the prevalence of blood disorders among the global population, and a surge in the number of blood donors. Furthermore, the rise in the prevalence rate of blood cancer and the increase in the prevalence of diseases such as malaria and cancer enhance the growth of this market. For instance, according to the data from Leukemia & Lymphoma Society, in 2021, new cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the estimated 1,898,160 new cancer cases in the U.S. This led to an increase in the requirement of patient blood management.
However, unfavorable reimbursements as well as high costs of instruments and devices that are used in patient blood management are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for patient blood management device manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth owing to a rise in chronic diseases and an increase in the number of surgical procedures performed, boosting the growth of the patient blood management market. Moreover, the increase in road accidents that cause blood loss, the rise in awareness regarding blood donation, and the increase in government expenditure on healthcare drive the growth of the patient blood management market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
In addition, rise in R&D investments in the discovery & development of safe and effective patient blood management devices, a significant rise in capital income in developed countries, and a rise in key strategies such as product launch, collaboration, merger, & acquisition adopted by key players strengthen demand for patient blood management devices in the market.
For instance, in July 2019, Grifols, a global healthcare company, and producer of plasma-derived medicines announced the acquisition of its first donation center in Canada as part of the company’s commitment to increase the availability of lifesaving plasma medicines in the country. In a share purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc’s (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. It is designed such that it can screen blood and plasma more efficiently within a smaller space than commercially available competitive systems. In a testing specialty that needs extensive hands-on time, the additional automation and flexibility of Alinity’s are expected to help blood and plasma centers improve productivity and maintain the highest levels of accuracy. Hence, such factors drive the growth of the patient blood management market.
The patient blood management market is segmented on the basis of product, component, end user, and region. On the basis of product, the market is classified into instruments (blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, and blood storage devices), accessories (syringes & needles, vials & tubes, blood bags, and others), reagents & kits (blood culture media, blood typing reagents, slide staining reagents, and assay kits), and software. On the basis of components, the market is classified into whole blood & red blood cells, and plasma. Depending on the end user, it is fragmented into hospitals, blood banks, and diagnostic clinics & pathology labs. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Asahi Kasei Corporation, B. Braun SE, BioMérieux, Inc., Grifols, S.A., Haemonetics Corporation, Haier Biomedical, Immucor, Inc., LivaNova PLC, Macopharma, and Terumo Corporation.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the patient blood management market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global patient blood management market trends, key players, market segments, application areas, and market growth strategies.
Patient Blood Management improves patient outcomes by improving the patient’s medical and surgical management in ways that boost and conserve the patient’s own blood. Owing to better management, patients usually require fewer transfusions of donated blood components, thus avoiding transfusion-associated complications. The National Blood Authority of Australia is funding and managing the development of evidence-based patient blood management guidelines.
Major factors driving the growth of the patient blood management market include a rise in technological advancement in patient blood management devices, an increase in the prevalence of blood disorders among the global population, and a surge in the number of blood donors. Furthermore, the rise in the prevalence rate of blood cancer and the increase in the prevalence of diseases such as malaria and cancer enhance the growth of this market. For instance, according to the data from Leukemia & Lymphoma Society, in 2021, new cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the estimated 1,898,160 new cancer cases in the U.S. This led to an increase in the requirement of patient blood management.
However, unfavorable reimbursements as well as high costs of instruments and devices that are used in patient blood management are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for patient blood management device manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth owing to a rise in chronic diseases and an increase in the number of surgical procedures performed, boosting the growth of the patient blood management market. Moreover, the increase in road accidents that cause blood loss, the rise in awareness regarding blood donation, and the increase in government expenditure on healthcare drive the growth of the patient blood management market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
In addition, rise in R&D investments in the discovery & development of safe and effective patient blood management devices, a significant rise in capital income in developed countries, and a rise in key strategies such as product launch, collaboration, merger, & acquisition adopted by key players strengthen demand for patient blood management devices in the market.
For instance, in July 2019, Grifols, a global healthcare company, and producer of plasma-derived medicines announced the acquisition of its first donation center in Canada as part of the company’s commitment to increase the availability of lifesaving plasma medicines in the country. In a share purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc’s (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. It is designed such that it can screen blood and plasma more efficiently within a smaller space than commercially available competitive systems. In a testing specialty that needs extensive hands-on time, the additional automation and flexibility of Alinity’s are expected to help blood and plasma centers improve productivity and maintain the highest levels of accuracy. Hence, such factors drive the growth of the patient blood management market.
The patient blood management market is segmented on the basis of product, component, end user, and region. On the basis of product, the market is classified into instruments (blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, and blood storage devices), accessories (syringes & needles, vials & tubes, blood bags, and others), reagents & kits (blood culture media, blood typing reagents, slide staining reagents, and assay kits), and software. On the basis of components, the market is classified into whole blood & red blood cells, and plasma. Depending on the end user, it is fragmented into hospitals, blood banks, and diagnostic clinics & pathology labs. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Asahi Kasei Corporation, B. Braun SE, BioMérieux, Inc., Grifols, S.A., Haemonetics Corporation, Haier Biomedical, Immucor, Inc., LivaNova PLC, Macopharma, and Terumo Corporation.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patient blood management market analysis from 2021 to 2031 to identify the prevailing patient blood management market opportunities.Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the patient blood management market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global patient blood management market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Component
- Whole Blood and Red Blood Cells
- Plasma
By End User
- Blood Banks
- Hospitals
- Diagnostic Clinics and Pathology Labs
By Product
- Instruments
- Type
- Blood Processing Devices
- Blood Transfusion Devices
- Blood Culture Screening Devices
- Diagnostic and Testing Instruments
- Blood Storage Devices
- Accessories
- Type
- Syringes and Needles
- Vials and Tubes
- Blood Bags
- Others
- Reagents and Kits
- Type
- Blood Culture Media
- Blood Typing Reagents
- Slide Staining Reagents
- Assay Kits
- Software
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Grifols, S.A.
- B. Braun SE
- Immucor, Inc
- Haemonetics Corporation
- LivaNova PLC
- Biomerieux SA
- Haier Biomedical
- Macopharma
- Terumo Corporation
- Asahi Kasei Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. High bargaining power of buyers
3.3.3. High threat of substitutes
3.3.4. High threat of new entrants
3.3.5. High intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in incidence of trauma and accidents
3.4.1.2. Increase in prevalence of blood cancer
3.4.1.3. Increase in government expenditure on healthcare
3.4.2. Restraints
3.4.2.1. Risks related to blood transfusion procedure
3.4.2.2. High cost of advanced patient blood management products
3.4.3. Opportunities
3.4.3.1. Rise in demand for blood and other blood related products across the globe
3.4.3.2. Surge in blood donations and plasma donations across the globe
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Instruments Patient Blood Management Market by Type
4.2.4.1. Blood Processing Devices Market size and forecast, by region
4.2.4.2. Blood Transfusion Devices Market size and forecast, by region
4.2.4.3. Blood Culture Screening Devices Market size and forecast, by region
4.2.4.4. Diagnostic and Testing Instruments Market size and forecast, by region
4.2.4.5. Blood Storage Devices Market size and forecast, by region
4.3. Accessories
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. Accessories Patient Blood Management Market by Type
4.3.4.1. Syringes and Needles Market size and forecast, by region
4.3.4.2. Vials and Tubes Market size and forecast, by region
4.3.4.3. Blood Bags Market size and forecast, by region
4.3.4.4. Others Market size and forecast, by region
4.4. Reagents and Kits
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.4.4. Reagents and Kits Patient Blood Management Market by Type
4.4.4.1. Blood Culture Media Market size and forecast, by region
4.4.4.2. Blood Typing Reagents Market size and forecast, by region
4.4.4.3. Slide Staining Reagents Market size and forecast, by region
4.4.4.4. Assay Kits Market size and forecast, by region
4.5. Software
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT
5.1. Overview
5.1.1. Market size and forecast
5.2. Whole Blood and Red Blood Cells
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Plasma
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: PATIENT BLOOD MANAGEMENT MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Blood Banks
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Hospitals
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Diagnostic Clinics and Pathology Labs
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PATIENT BLOOD MANAGEMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Product
7.2.2.1. North America Instruments Patient Blood Management Market by Type
7.2.2.2. North America Accessories Patient Blood Management Market by Type
7.2.2.3. North America Reagents and Kits Patient Blood Management Market by Type
7.2.3. Market size and forecast, by Component
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Product
7.2.5.1.3. Market size and forecast, by Component
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Product
7.2.5.2.3. Market size and forecast, by Component
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Product
7.2.5.3.3. Market size and forecast, by Component
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Product
7.3.2.1. Europe Instruments Patient Blood Management Market by Type
7.3.2.2. Europe Accessories Patient Blood Management Market by Type
7.3.2.3. Europe Reagents and Kits Patient Blood Management Market by Type
7.3.3. Market size and forecast, by Component
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Product
7.3.5.1.3. Market size and forecast, by Component
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Product
7.3.5.2.3. Market size and forecast, by Component
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Product
7.3.5.3.3. Market size and forecast, by Component
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Product
7.3.5.4.3. Market size and forecast, by Component
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Product
7.3.5.5.3. Market size and forecast, by Component
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Product
7.3.5.6.3. Market size and forecast, by Component
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Product
7.4.2.1. Asia-Pacific Instruments Patient Blood Management Market by Type
7.4.2.2. Asia-Pacific Accessories Patient Blood Management Market by Type
7.4.2.3. Asia-Pacific Reagents and Kits Patient Blood Management Market by Type
7.4.3. Market size and forecast, by Component
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Product
7.4.5.1.3. Market size and forecast, by Component
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Product
7.4.5.2.3. Market size and forecast, by Component
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Product
7.4.5.3.3. Market size and forecast, by Component
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Product
7.4.5.4.3. Market size and forecast, by Component
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Product
7.4.5.5.3. Market size and forecast, by Component
7.4.5.5.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Product
7.5.2.1. LAMEA Instruments Patient Blood Management Market by Type
7.5.2.2. LAMEA Accessories Patient Blood Management Market by Type
7.5.2.3. LAMEA Reagents and Kits Patient Blood Management Market by Type
7.5.3. Market size and forecast, by Component
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Product
7.5.5.1.3. Market size and forecast, by Component
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Product
7.5.5.2.3. Market size and forecast, by Component
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Product
7.5.5.3.3. Market size and forecast, by Component
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Product
7.5.5.4.3. Market size and forecast, by Component
7.5.5.4.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Asahi Kasei Corporation
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. B. Braun SE
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Biomerieux SA
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Grifols, S.A.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Haemonetics Corporation
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Haier Biomedical
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Immucor, Inc
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. LivaNova PLC
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Macopharma
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Terumo Corporation
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
List of Tables
Table 01. Global Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 02. Patient Blood Management Market for Instruments, by Region, 2021-2031 (Revenue, $Million)
Table 03. Global Instruments Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 04. Patient Blood Management Market for Blood Processing Devices, by Region, 2021-2031 (Revenue, $Million)
Table 05. Patient Blood Management Market for Blood Transfusion Devices, by Region, 2021-2031 (Revenue, $Million)
Table 06. Patient Blood Management Market for Blood Culture Screening Devices, by Region, 2021-2031 (Revenue, $Million)
Table 07. Patient Blood Management Market for Diagnostic and Testing Instruments, by Region, 2021-2031 (Revenue, $Million)
Table 08. Patient Blood Management Market for Blood Storage Devices, by Region, 2021-2031 (Revenue, $Million)
Table 09. Patient Blood Management Market for Accessories, by Region, 2021-2031 (Revenue, $Million)
Table 10. Global Accessories Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 11. Patient Blood Management Market for Syringes and Needles, by Region, 2021-2031 (Revenue, $Million)
Table 12. Patient Blood Management Market for Vials and Tubes, by Region, 2021-2031 (Revenue, $Million)
Table 13. Patient Blood Management Market for Blood Bags, by Region, 2021-2031 (Revenue, $Million)
Table 14. Patient Blood Management Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 15. Patient Blood Management Market for Reagents and Kits, by Region, 2021-2031 (Revenue, $Million)
Table 16. Global Reagents and Kits Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 17. Patient Blood Management Market for Blood Culture Media, by Region, 2021-2031 (Revenue, $Million)
Table 18. Patient Blood Management Market for Blood Typing Reagents, by Region, 2021-2031 (Revenue, $Million)
Table 19. Patient Blood Management Market for Slide Staining Reagents, by Region, 2021-2031 (Revenue, $Million)
Table 20. Patient Blood Management Market for Assay Kits, by Region, 2021-2031 (Revenue, $Million)
Table 21. Patient Blood Management Market for Software, by Region, 2021-2031 (Revenue, $Million)
Table 22. Global Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 23. Patient Blood Management Market for Whole Blood and Red Blood Cells, by Region, 2021-2031 (Revenue, $Million)
Table 24. Patient Blood Management Market for Plasma, by Region, 2021-2031 (Revenue, $Million)
Table 25. Global Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 26. Patient Blood Management Market for Blood Banks, by Region, 2021-2031 (Revenue, $Million)
Table 27. Patient Blood Management Market for Hospitals, by Region, 2021-2031 (Revenue, $Million)
Table 28. Patient Blood Management Market for Diagnostic Clinics and Pathology Labs, by Region, 2021-2031 (Revenue, $Million)
Table 29. Patient Blood Management Market, by Region, 2021-2031 (Revenue, $Million)
Table 30. North America Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 31. North America Instruments Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 32. North America Accessories Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 33. North America Reagents and Kits Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 34. North America Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 35. North America Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 36. North America Patient Blood Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 37. U.S. Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 38. U.S. Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 39. U.S. Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 40. Canada Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 41. Canada Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 42. Canada Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 43. Mexico Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 44. Mexico Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 45. Mexico Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 46. Europe Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 47. Europe Instruments Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 48. Europe Accessories Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 49. Europe Reagents and Kits Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 50. Europe Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 51. Europe Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 52. Europe Patient Blood Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 53. Germany Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 54. Germany Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 55. Germany Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 56. France Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 57. France Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 58. France Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 59. UK Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 60. UK Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 61. UK Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 62. Italy Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 63. Italy Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 64. Italy Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 65. Spain Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 66. Spain Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 67. Spain Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 68. Rest of Europe Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 69. Rest of Europe Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 70. Rest of Europe Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 71. Asia-Pacific Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 72. Asia-Pacific Instruments Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 73. Asia-Pacific Accessories Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 74. Asia-Pacific Reagents and Kits Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 75. Asia-Pacific Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 76. Asia-Pacific Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 77. Asia-Pacific Patient Blood Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 78. China Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 79. China Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 80. China Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 81. Japan Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 82. Japan Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 83. Japan Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 84. India Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 85. India Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 86. India Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 87. Australia Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 88. Australia Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 89. Australia Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 90. Rest of Asia-Pacific Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 91. Rest of Asia-Pacific Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 92. Rest of Asia-Pacific Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 93. LAMEA Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 94. LAMEA Instruments Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 95. LAMEA Accessories Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 96. LAMEA Reagents and Kits Patient Blood Management Market, by Type, 2021-2031 (Revenue, $Million)
Table 97. LAMEA Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 98. LAMEA Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 99. LAMEA Patient Blood Management Market, by Country, 2021-2031 (Revenue, $Million)
Table 100. Brazil Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 101. Brazil Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 102. Brazil Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 103. Saudi Arabia Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 104. Saudi Arabia Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 105. Saudi Arabia Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 106. South Africa Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 107. South Africa Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 108. South Africa Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 109. Rest of LAMEA Patient Blood Management Market, by Product, 2021-2031 (Revenue, $Million)
Table 110. Rest of LAMEA Patient Blood Management Market, by Component, 2021-2031 (Revenue, $Million)
Table 111. Rest of LAMEA Patient Blood Management Market, by End-user, 2021-2031 (Revenue, $Million)
Table 112. Asahi Kasei Corporation: Key Executives
Table 113. Asahi Kasei Corporation: Company Snapshot
Table 114. Asahi Kasei Corporation: Product Segments
Table 115. Asahi Kasei Corporation: Product Portfolio
Table 116. B. Braun Se: Key Executives
Table 117. B. Braun Se: Company Snapshot
Table 118. B. Braun Se: Product Segments
Table 119. B. Braun Se: Product Portfolio
Table 120. Biomerieux Sa: Key Executives
Table 121. Biomerieux Sa: Company Snapshot
Table 122. Biomerieux Sa: Product Segments
Table 123. Biomerieux Sa: Product Portfolio
Table 124. Grifols, S.A.: Key Executives
Table 125. Grifols, S.A.: Company Snapshot
Table 126. Grifols, S.A.: Product Segments
Table 127. Grifols, S.A.: Product Portfolio
Table 128. Grifols, S.A.: Key Stratergies
Table 129. Haemonetics Corporation: Key Executives
Table 130. Haemonetics Corporation: Company Snapshot
Table 131. Haemonetics Corporation: Product Segments
Table 132. Haemonetics Corporation: Product Portfolio
Table 133. Haemonetics Corporation: Key Stratergies
Table 134. Haier Biomedical: Key Executives
Table 135. Haier Biomedical: Company Snapshot
Table 136. Haier Biomedical: Product Segments
Table 137. Haier Biomedical: Product Portfolio
Table 138. Immucor, Inc: Key Executives
Table 139. Immucor, Inc: Company Snapshot
Table 140. Immucor, Inc: Product Segments
Table 141. Immucor, Inc: Product Portfolio
Table 142. Livanova plc: Key Executives
Table 143. Livanova plc: Company Snapshot
Table 144. Livanova plc: Product Segments
Table 145. Livanova plc: Product Portfolio
Table 146. Macopharma: Key Executives
Table 147. Macopharma: Company Snapshot
Table 148. Macopharma: Product Segments
Table 149. Macopharma: Product Portfolio
Table 150. Terumo Corporation: Key Executives
Table 151. Terumo Corporation: Company Snapshot
Table 152. Terumo Corporation: Product Segments
Table 153. Terumo Corporation: Product Portfolio
Table 154. Terumo Corporation: Key Stratergies
List of Figures
Figure 01. Patient Blood Management Market, 2021-2031
Figure 02. Segmentation of Patient Blood Management Market, 2021-2031
Figure 03. Top Investment Pockets in Patient Blood Management Market (2022-2031)
Figure 04. High Bargaining Power of Suppliers
Figure 05. High Bargaining Power of Buyers
Figure 06. High Threat of Substitutes
Figure 07. High Threat of New Entrants
Figure 08. High Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalpatient Blood Management Market
Figure 10. Patient Blood Management Market, by Product, 2021 (%)
Figure 11. Comparative Share Analysis of Patient Blood Management Market for Instruments, by Country 2021-2031 (%)
Figure 12. Comparative Share Analysis of Patient Blood Management Market for Accessories, by Country 2021-2031 (%)
Figure 13. Comparative Share Analysis of Patient Blood Management Market for Reagents and Kits, by Country 2021-2031 (%)
Figure 14. Comparative Share Analysis of Patient Blood Management Market for Software, by Country 2021-2031 (%)
Figure 15. Patient Blood Management Market, by Component, 2021 (%)
Figure 16. Comparative Share Analysis of Patient Blood Management Market for Whole Blood and Red Blood Cells, by Country 2021-2031 (%)
Figure 17. Comparative Share Analysis of Patient Blood Management Market for Plasma, by Country 2021-2031 (%)
Figure 18. Patient Blood Management Market, by End-user, 2021 (%)
Figure 19. Comparative Share Analysis of Patient Blood Management Market for Blood Banks, by Country 2021-2031 (%)
Figure 20. Comparative Share Analysis of Patient Blood Management Market for Hospitals, by Country 2021-2031 (%)
Figure 21. Comparative Share Analysis of Patient Blood Management Market for Diagnostic Clinics and Pathology Labs, by Country 2021-2031 (%)
Figure 22. Patient Blood Management Market by Region, 2021
Figure 23. U.S. Patient Blood Management Market, 2021-2031 ($Million)
Figure 24. Canada Patient Blood Management Market, 2021-2031 ($Million)
Figure 25. Mexico Patient Blood Management Market, 2021-2031 ($Million)
Figure 26. Germany Patient Blood Management Market, 2021-2031 ($Million)
Figure 27. France Patient Blood Management Market, 2021-2031 ($Million)
Figure 28. UK Patient Blood Management Market, 2021-2031 ($Million)
Figure 29. Italy Patient Blood Management Market, 2021-2031 ($Million)
Figure 30. Spain Patient Blood Management Market, 2021-2031 ($Million)
Figure 31. Rest of Europe Patient Blood Management Market, 2021-2031 ($Million)
Figure 32. China Patient Blood Management Market, 2021-2031 ($Million)
Figure 33. Japan Patient Blood Management Market, 2021-2031 ($Million)
Figure 34. India Patient Blood Management Market, 2021-2031 ($Million)
Figure 35. Australia Patient Blood Management Market, 2021-2031 ($Million)
Figure 36. Rest of Asia-Pacific Patient Blood Management Market, 2021-2031 ($Million)
Figure 37. Brazil Patient Blood Management Market, 2021-2031 ($Million)
Figure 38. Saudi Arabia Patient Blood Management Market, 2021-2031 ($Million)
Figure 39. South Africa Patient Blood Management Market, 2021-2031 ($Million)
Figure 40. Rest of LAMEA Patient Blood Management Market, 2021-2031 ($Million)
Figure 41. Top Winning Strategies, by Year
Figure 42. Top Winning Strategies, by Development
Figure 43. Top Winning Strategies, by Company
Figure 44. Product Mapping of Top 10 Players
Figure 45. Competitive Dashboard
Figure 46. Competitive Heatmap: Patient Blood Management Market
Figure 47. Top Player Positioning, 2021
Figure 48. Asahi Kasei Corporation: Net Sales, 2019-2021 ($Million)
Figure 49. Asahi Kasei Corporation: Revenue Share by Segment, 2021 (%)
Figure 50. Asahi Kasei Corporation: Revenue Share by Region, 2021 (%)
Figure 51. B. Braun Se: Net Sales, 2019-2021 ($Million)
Figure 52. B. Braun Se: Revenue Share by Segment, 2021 (%)
Figure 53. B. Braun Se: Revenue Share by Region, 2021 (%)
Figure 54. Biomerieux Sa: Net Sales, 2019-2021 ($Million)
Figure 55. Biomerieux Sa: Revenue Share by Segment, 2021 (%)
Figure 56. Biomerieux Sa: Revenue Share by Region, 2021 (%)
Figure 57. Grifols, S.A.: Net Revenue, 2019-2021 ($Million)
Figure 58. Grifols, S.A.: Revenue Share by Segment, 2021 (%)
Figure 59. Grifols, S.A.: Revenue Share by Region, 2021 (%)
Figure 60. Haemonetics Corporation: Net Revenue, 2019-2021 ($Million)
Figure 61. Haemonetics Corporation: Revenue Share by Segment, 2021 (%)
Figure 62. Haemonetics Corporation: Revenue Share by Region, 2021 (%)
Figure 63. Livanova plc: Net Revenue, 2019-2021 ($Million)
Figure 64. Livanova plc: Revenue Share by Segment, 2021 (%)
Figure 65. Livanova plc: Revenue Share by Region, 2021 (%)
Figure 66. Terumo Corporation: Net Revenue, 2019-2021 ($Million)
Figure 67. Terumo Corporation: Revenue Share by Segment, 2021 (%)
Figure 68. Terumo Corporation: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, “Patient Blood Management Market," The patient blood management market was valued at $12.2 billion in 2021, and is estimated to reach $22.1 billion by 2031, growing at a CAGR of 6.3% from 2022 to 2031.Patient blood management is a type of medical practice that improves the health of a patient’s own blood. Under patient blood management, a multidisciplinary team determines, with the patient, the specific management plan, which makes every reasonable endeavor to optimize the patient’s own blood volume, minimize blood loss, and optimize the patient’s physiological tolerance of anemia.
Key factors driving the growth of the patient blood management market include a rise in the prevalence of blood disorders (such as sickle cell anemia, and hemophilia), infectious diseases, bloodstream infection, an increase in cases of leukemia, and lymphoma, and a rise in the incidence of trauma and accidents. In addition, the increase in focus to follow patient blood management guidelines, government activities to raise awareness about blood donation, and the increase in the number of surgical procedures performed drive the growth of the patient blood management market.
The market also offers growth opportunities to the key players in the market including a surge in blood donations & plasma donations and a rise in demand for blood and other blood-related products across the globe. As a result, the key players engaged in the medical devices industry have invested in R&D for the discovery of new patient blood management products that are expected to gain high traction and provide lucrative opportunities for the growth of the patient blood management market.
The patient blood management market is segmented on the basis of product, component, end user, and region. On the basis of product, the market is classified into instruments (blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, and blood storage devices), accessories (syringes & needles, vials & tubes, blood bags, and others), reagents & kits (blood culture media, blood typing reagents, slide staining reagents, and assay kits), and software. On the basis of components, the market is classified into whole blood & red blood cells, and plasma. Depending on the end user, it is fragmented into hospitals, blood banks, and diagnostic clinics & pathology labs. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Asahi Kasei Corporation, B. Braun SE, BioMérieux, Inc., Grifols, S.A., Haemonetics Corporation, Haier Biomedical, Immucor, Inc., LivaNova PLC, Macopharma, and Terumo Corporation. The players in the market have been actively engaged in the adoption of various strategies such as collaboration to remain competitive and gain an advantage over the competitors in the market. For instance, in July 2021, Grifols S.A. a global leader in the manufacturing of plasma-derived medicines collaborated with the U.S. firm ImmunoTek Bio Centers LLC, for the development of 21 plasma collection centers.
Key Market Insights
- By product, the instruments segment was the highest revenue contributor to the market in 2021 and is estimated to reach $ 8,795.3 million by 2031. The reagents and kits segment is expected to be the fastest-growing segment with a CAGR of 6.8% during the forecast period.
- By component, the whole blood and red blood cells segment was the highest revenue contributor to the market in 2021. The plasma segment is expected to witness the highest CAGR of 6.5%.
- Based on end users, the hospital segment was the highest revenue contributor to the market in 2021. However, the diagnostic clinics and pathology labs segment is estimated to be the fastest-growing segment with a CAGR of 6.6% during the forecast period.
- Based on region, Asia-Pacific witnessed the highest growth in 2021 and is expected to witness the highest CAGR of 7.2% during the forecast period.
Companies Mentioned
- Grifols, S.A.
- B. Braun SE
- Immucor, Inc
- Haemonetics Corporation
- LivaNova PLC
- Biomerieux SA
- Haier Biomedical
- Macopharma
- Terumo Corporation
- Asahi Kasei Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
